Gustavo Rodrigues Pedrino

Graduated in Biological Sciences, with a specialization in the Medical Modality, from the Federal University of São Paulo (UNIFESP, 2002), he obtained a Master of Science degree through the Graduate Program in Pharmacology, with a concentration in Physiology, from the same institution (2005). He completed his Ph.D. in Science in the aforementioned program (2009), having conducted part of his doctoral training at the Department of Physiology of the University of Texas Health Science Center at San Antonio. Currently, he is an Associate Professor IV in the Department of Physiological Sciences at the Institute of Biological Sciences of the Federal University of Goiás (ICB/UFG), where he coordinates the Research Laboratory for Neural and Cardiovascular Pathophysiology. In the administrative sphere, he has held the positions of Coordinator of the Multicenter Graduate Program in Physiological Sciences (2012-2013) and Coordinator of the Undergraduate Program in Biomedicine at ICB/UFG (2014-2018). Furthermore, he has played significant roles within the Brazilian Society of Physiology (SBFis), serving as Treasurer (2019-2020) and President of its Deliberative Council (2021-2024). He holds the positions of Director of ICB/UFG (2018-2026), President-Elect of SBFis (2025-2026), and Treasurer of the Federation of Experimental Biology Societies (FeSBE, 2022-2025). He is a Level 1C Research Productivity Fellow of the Biophysics, Pharmacology, Physiology, and Neurosciences Committee of the National Council for Scientific and Technological Development (CNPq, 2020-2029). His scientific research focuses on elucidating the pathophysiological mechanisms of cardiovascular and metabolic diseases, specifically addressing: i) The neural pathways and mechanisms involved in the onset and maintenance of cardiovascular and metabolic disorders; ii) The characterization of polymorphisms in angiotensin-converting enzyme I (ACE I) and II (ACE II) and their correlations with susceptibility to cardiovascular diseases; iii) The influence of metabolic programming during critical periods of ontogenetic development on the susceptibility to cardiometabolic diseases; iv) The development and preclinical validation of pharmacological prototypes and herbal compounds with therapeutic potential for cardiometabolic diseases. (Source: Lattes Curriculum)